Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BACC Bay Tocilizumab Trial
NCT04356937Phase 3Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2020
- Primary completion
- Jul 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab in coronavirus disease 2019 (COVID-19), sponsored by Massachusetts General Hospital. Started Apr 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04356937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04356937.